Trials / Completed
CompletedNCT00993915
Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 687 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant diseases and cardiovascular risk factor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin | Atorvastatin, 10- 80 mg, once daily, 6 month treatment |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2009-10-14
- Last updated
- 2021-02-18
- Results posted
- 2012-12-20
Source: ClinicalTrials.gov record NCT00993915. Inclusion in this directory is not an endorsement.